GTS Securities’s Rhythm Pharmaceuticals RYTM Stock Holding History

GTS Securities’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-23,136	Closed	-$1.11M	–	4391
2024 Q2	$950K	Buy	+23,136	New	+$924K	﹤0.01%	2093

Other funds holding RYTM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GTS Securities's RYTM Position: Q3 2024 in Review

GTS Securities sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2024, closing a stake of 23,136 shares — an estimated $1.11M sold.

GTS Securities first reported a position in RYTM in Q2 2024 and held it in 1 quarter. The position peaked at $950K in Q2 2024. 176 funds tracked by Wall St. Rank hold RYTM as of Q3 2024.

GTS Securities reported no remaining Rhythm Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
GTS Securities sold 23,136 Rhythm Pharmaceuticals shares in Q3 2024, an estimated $1.11M.
GTS Securities first reported a position in Rhythm Pharmaceuticals in Q2 2024 and held it in 1 quarter.
GTS Securities's Rhythm Pharmaceuticals position peaked at $950K in Q2 2024.
176 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2024.

Based on GTS Securities's 13F filing for Q3 2024, filed 13 Nov 2024.